trofosfamide has been researched along with Disease Exacerbation in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atzpodien, J; Fluck, M; Morawek, L; Reitz, M | 1 |
| Dörken, B; Kretzschmar, A; Pink, D; Reichardt, P; Thuss-Patience, PC; Tilgner, J | 1 |
| Andreesen, R; Bataille, F; Berand, A; Bross, K; Hafner, C; Jauch, KW; Landthaler, M; Reichle, A; Vogt, T | 1 |
| Enk, AH; Knop, J | 1 |
| Deininger, MH; Grote, E; Meyermann, R; Wickboldt, J | 1 |
1 trial(s) available for trofosfamide and Disease Exacerbation
| Article | Year |
|---|---|
Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Hemangioendothelioma; Hemangiosarcoma; Humans; Lactones; Male; Middle Aged; Pioglitazone; Sulfones; Thiazolidinediones; Treatment Outcome | 2003 |
4 other study(ies) available for trofosfamide and Disease Exacerbation
| Article | Year |
|---|---|
Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Survival Analysis; Vinblastine; Vinorelbine | 2009 |
Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms | 2002 |
[Stabilizing the course of patients with stage IV advanced malignant melanoma by trofosfamide treatment].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Treatment Outcome | 2000 |
Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Brain Neoplasms; Cell Division; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Genes; Genes, bcl-2; Glioblastoma; GTP-Binding Proteins; Humans; Ki-67 Antigen; Life Tables; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Nimustine; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-bcl-2; Radiotherapy, Adjuvant; Survival Analysis; Teniposide; Transglutaminases; Tumor Suppressor Protein p53 | 2000 |